3Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and man- agement of hemochromatosis: 2011 practice guideline by the A- merican Association for the Study of Liver Diseases. Hepatology, 2011,54( 1 ) :328-343.
3Valenti L, Pulixi EA, Arosio P, et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus(HCV) in the pathogen- esis of altered iron regulation in HCV chronic hepatitis [ J ]. Haematologica ,2007,92 : 1037 - 1042.
4Nordestgaard BG, Adourian AS, Freiberg JJ, et al. Risk factors for near-term myocardial infarction in apparently healthy men and women [ J ]. Clin Chem,2010 ,56 :559 - 567.
5McClain DA, Abraham D, Rogers J, et al. High prevalence of ab- normal glucose homeostasis secondary to decreased insulin secre- tion in individuals with hereditary haemochromatosis[ J]. Diabeto- logia,2006,49 : 1661 - 1669.
6Au WY,Lam WW,Chu W,et al. A T2 magnetic resonance imaging study of pancreatic iron overload in thalassemia major[ J]. Haema- tologica,2008,93 : 116 - 119.
7Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome[ J]. Haematalogica,2006,91 : 1588 - 1590.
8Kattamis A, Dinopoulos A, Ladis V, et al. Variations of ferritin lev- els over a period of 15 years as a compliance chelation index in thalassemic patients [ J ]. Am J Hematol,2001,68 :221 - 224.
9Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload [ J ]. Expert Opin Pharmacother, 2008, 9:2391 - 2402.
10LEITCH H A.Improving clinical outcomes in patients with myelodysplastic syndrome and iron overload using iron chelation therapy[J].Leuk Res,2007,31(suppl 3):S7-S9.
